IM-1021 — Initial data
2026
Immunome expects to present initial lymphoma data for IM-1021 in 2026.Source filing
IMNM biotech catalysts & pipeline
IMMUNOME INC · Data as of 2026-09-08
Upcoming catalysts
IM-1340 — IND submission
2026
Preclinical Pipeline : Immunome's three preclinical ADCs against solid tumor targets, IM-1617, IM-1340 and IM-1335, each of which incorporates HC74, continue to advance towards 2026 IND submissions.Source filing
IM-1617 — IND submission
2026
Preclinical Pipeline : Immunome's three preclinical ADCs against solid tumor targets, IM-1617, IM-1340 and IM-1335, each of which incorporates HC74, continue to advance towards 2026 IND submissions.Source filing
solid tumor-targeted ADC programs — IND submission
2026
Three IND submissions for solid tumor-targeted ADC programs planned in 2026Source filing
IM-1335 — IND submission
late 2026
Immunome expects to submit Investigational New Drug applications (INDs) for IM-1340 and IM-1335 in mid- and late 2026, respectively.Source filing
varegacestat (formerly AL102) — NDA/BLA submission
Late 2026
Immunome plans to submit a Marketing Authorization Application to the European Medicines Agency for varegacestat by the end of 2026.Source filing
varegacestat (formerly AL102) — PDUFA
Apr 28
Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumorsSource filing